Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Am J Hematol. 2020 Dec 24;96(3):282–291. doi: 10.1002/ajh.26061

Fig 2.

Fig 2.

a. Event-free survival (EFS) in patients who received 10-day decitabine with venetoclax (DEC10-VEN) and intensive chemotherapy (IC), b. EFS in patients with high treatment-related mortality risk score (TRMS >13.1), c. EFS in patients with low risk of TRM (TRMS ≤13.1), d. EFS with DEC10-VEN in patients at high and low risk of TRM.